

Title of case report or series
Infantile Hypercalcaemia Type 1: a Vitamin D-mediated, under-recognised cause of hypercalcaemia
Authors
<ol style="list-style-type: none"> 1. Ryizan Nizar – Department of Diabetes and Endocrinology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK 2. Nathan WP Cantley – Department of Clinical Biochemistry, Southmead Hospital, North Bristol NHS Trust, Bristol, UK 3. Jonathan CY Tang – Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.
Corresponding Author – Dr Ryizan Nizar – r.nizar@nhs.net
Summary
<p>A 33 year old gentleman of Egyptian heritage presented with a 21 year history of unexplained and recurrent hypercalcaemia, nephrolithiasis, nephrocalcinosis and myocarditis. A similar history was also found in two first-degree relatives. Further investigation into the Vitamin D metabolism pathway identified the biochemical hallmarks of Infantile Hypercalcaemia Type 1 (IIH) [1]. A homozygous, likely pathogenic, variant in <i>CYP24A1</i> was found on molecular genetic analysis confirming the diagnosis. Management now focuses on removing excess Vitamin D from the metabolic pathway as well as reducing calcium intake to achieve serum adjusted calcium to the middle of the reference range. If undiagnosed, IIH can cause serious renal complications and metabolic bone disease.</p>
Learning points
<ul style="list-style-type: none"> • Infantile hypercalcaemia Type 1 (IIH) is an autosomal recessive disorder characterised by homozygous mutations in the <i>CYP24A1</i> gene that encodes the 24-hydroxylase enzyme used to convert active Vitamin D metabolites such as 1,25-(OH)₂-Vitamin D, into their inactive form. • IIH should be questioned in individuals presenting with a history of unexplained hypercalcaemia, especially if presenting from childhood and/or where there is an accompanying family history of the same in 1st and/or 2nd degree relatives, causing complications such as nephrocalcinosis, pericarditis and calcium based nephrolithiasis. • Associated biochemistry of IIH is persistent mild to moderate hypercalcaemia, normal or raised 25-(OH)-Vitamin D and elevated 1,25-(OH)₂-Vitamin D. An elevated ratio of 25-(OH)-Vitamin D to 24,25-(OH)₂-Vitamin D can be a useful marker of defects in the 24-hydroxylase enzyme, whose measurement can be facilitated through the supra-regional assay service • Management should focus on limiting the amount of Vitamin D introduced into the body either via sunlight exposure or supplementation in addition to calcium dietary restriction to try and maintain appropriate calcium homeostasis
Background
<p>Vitamin D excess, either as a result of excess intake or reduced inactivation/excretion, is recognised to be a cause of hypercalcaemia, although seldom considered. Subtle elevations in the 25-(OH) and 1,25-(OH)₂ forms of Vitamin D can go unnoticed and be poorly understood. The condition we describe here is under-recognised in clinical practice. When these individuals are eventually diagnosed as adults, they commonly are found to have had biochemical/pathological features extending back from childhood [2]. We present this case to provide further education and prevent other patients from undergoing the same significant delay in appropriate diagnosis.</p>
Case presentation
<p>A 33 year old gentleman of Egyptian heritage incidentally came to the attention of endocrinology during an admission to acute medicine presenting with symptoms of chest pain thought to be the 8th presentation in 4 years with myocarditis associated symptoms. Cause for the myocarditis was documented in cardiology outpatient letters as being “undetermined.” The patient did not have any other classical features on history or examination associated with hypercalcaemia on this presentation.</p> <p>The patient had an extensive past medical history of renal calculi- first presenting at age 12 whilst still living in Egypt. Subsequent repeat renal calculi developed at age 16 and 17. The patient had an otherwise normal development history through his childhood. He then presented to urology services in the UK as an adult due to hydronephrosis secondary to renal calculi. Both brother and father of this patient also suffered from nephrolithiasis indicating a possible genetic aetiology to the shared symptoms. The patient had also been</p>

<p>reviewed in a metabolic renal stone clinic.</p> <p>The patient did not have specific findings on clinical examination aside from the symptoms associated with the myocarditis of chest pain and shortness of breath, and renal angle abdominal pain whenever renal calculi arose.</p>
<p>Investigation</p> <p>A summary of biochemical and radiological investigations is documented in Table 1. Other investigations performed include renal calculus analysis by infrared spectroscopy in 2009 which revealed 98% content of the extracted calculus was calcium phosphate. Repeated oxalate and citrate output demonstrated results either within the reference range or only mildly elevated (Citrate output- 1.4mmol/24hrs [reference range - 1.3-6.0mmol/24hrs], Oxalate output- 380umol/24hrs [reference range <460umol/24hrs]). Fibroblast Growth Factor-23 (FGF-23) and Retinol binding protein (RBP) levels were checked historically as part of his initial work up in 2011 and were within the reference range when measured (RBP/creatinine ratio – 5.0ug/mmol creatinine [reference range <18ug/mmol creatinine], FGF23 – 93RU/ml [reference range <100RU/ml]). FGF-23 is one of the most important regulators of serum phosphate and 1,25-(OH)₂-Vitamin D levels. High levels of FGF 23 suppresses the activity of 1-Alfa Hydroxylase activity leading to low 1,25-(OH)₂-Vitamin D levels [3]. However FGF-23 deficiency or resistance can lead to a state of high 1,25-(OH)₂-Vitamin D levels with high phosphate levels. There are hereditary and acquired forms of FGF-23 deficiency/resistance and this manifest with tumoral calcinosis [3]. RBP is used by renal physicians to rule out renal tubular injury as a cause of underlying renal disease. This patient had been followed up by the renal team for number of years for unexplained nephrocalcinosis and he would have had a RBP level checked initially to rule out Renal tubular damage.</p> <p>As part of this patients Hypercalcemia work up he also had a DEXA scan showed consistent signs of osteopenia (T-score between -1 to -2.5) within the lumbar spine region.</p> <p>In June 2020, a 24,25-(OH)₂-Vitamin D level performed at Norwich and Norfolk Hospital Supra-regional assay lab returned a result of 1.2nmol/L (reference range- 1.1-13.5nmol/L). With an accompanying 25-OH-Vitamin D of 79nmol/L, this yielded a significantly elevated 25-OH-Vitamin D to 24,25-(OH)₂-Vitamin D ratio of 66 (upper limit of normal = 23). A mildly elevated 1,25-(OH)₂-Vitamin D (153pmol/L [reference range 55-139nmol/L]) means the ratio of 1,25-(OH)₂-Vitamin D to 24,25-(OH)₂-Vitamin D was extremely high at 128, a further feature of IIH. Genetic analysis by next-generation sequencing of <i>CYP24A1</i> revealed a biallelic 3 base pair deletion at codon 143 (Glu143del) that has a deleterious effect on the enzyme and classified as a class 4 variant (likely pathogenic) [4]. Given both biochemical and genetic hallmarks were concordant – a diagnosis of IIH was made.</p>
<p>Treatment</p> <p>Prior to the diagnosis, the patient was prescribed: Indapamide 2.5mg once daily, Nebivolol 2.5mg twice daily. The treatment plan for this patient following diagnosis aimed to reduce his intake of dietary calcium as well as any medications which could exacerbate hypercalcaemia. Additionally, exogenous sources of Vitamin D which could exacerbate his 1,25-(OH)₂-Vitamin D were removed. The summary of the initial treatment plan was as follows:</p> <ul style="list-style-type: none"> • Avoid all exogenous Vitamin D supplementation • Avoid prolonged sun exposure which may increase production of active vitamin D • Reduce dietary calcium intake titrating this against achieving a serum calcium within the middle of the reference range (2.2-2.6mmol/L) <p>If this failed to correct his serum calcium then next treatment trial would be oral fluconazole. Acute presentations with markedly elevated serum calcium levels could be treated with short courses of prednisolone to inhibit 1,25-(OH)₂-Vitamin D levels.</p>
<p>Outcome and follow-up</p> <p>As a first step, Renal Dietetic input will start working to achieve a low calcium diet and instructions to care providers for the patient to not introduce any exogenous sources of Vitamin D. At time of manuscript submission, this has been slow to initiate, but regular follow-up is planned on diet adherence with repeated biochemistry, to identify if next line therapy (trial of fluconazole) is indicated. Other first degree relatives of the patient have been advised to be screened for the same mutation to confirm carrier/affected status of the parents and siblings respectively.</p>
<p>Discussion</p>

<p>IIH is a rare condition with its prevalence in the general population unknown [1]. In the UK, there had been concerns of Vitamin D induced Hypercalcaemia in some children as far back as the 1950's. Interestingly this was the same time at which Vitamin D supplementation or food fortification was introduced to prevent Rickets disease. There were 204 reported cases within a two year period up to July 1955 [2]. In the vast majority it was thought to be due to high intake of Vitamin D. This would suggest disorders of Vitamin D metabolism are more prevalent but only some present with symptoms due to phenotypic variability [5]. Infantile Hypercalcaemia is not a "benign" condition as initially postulated and in our patient he experienced Nephrocalcinosis, Osteopenia, GI symptoms and pericarditis [4].</p> <p>There are two known causative genes/"types" of Infantile Hypercalcaemia. Type 1 is caused by loss of function mutation in <i>CYP24A1</i> whilst Type 2 is caused by mutation in <i>SLC34A1</i> gene. Mutation in <i>CYP24A1</i> leads to the phenotype we describe here (figure 1). Mutation in <i>SLC34A1</i> reduces serum phosphate levels due to a defect in sodium dependant phosphate transporters, leading to low body stores of phosphates, and for which more Vitamin D is activated to compensate.</p> <p>Pragmatically for clinical practice, a pattern of high calcium, low PTH in a young person with no concerns of malignancy should prompt to check 1,25-(OH)₂-Vitamin D level in addition to 25-OH-Vitamin D. An inappropriately high 1,25-(OH)₂-Vitamin D levels should prompt reflection on possible causes related to Vitamin D metabolism and further testing of other Vitamin D metabolites. Persistently high level of 1,25-(OH)₂-Vitamin D leads to increased intestinal absorption of Calcium as well as increased bone resorption. This sustained bone resorption leads to the osteopenia/osteoporosis described in this case [6].</p> <p>Measurement of 24,25-(OH)₂-Vitamin D is available to request through the supra-regional Vitamin D assay service at Norwich and Norfolk Hospitals in partnership with University of East Anglia [7]. This uses a liquid-chromatography, tandem mass spectroscopy (LC-MS/MS) method and provides a level of 24,25-(OH)₂-Vitamin D as well as a ratio of 25-(OH)-Vitamin D to 24,25-(OH)₂-Vitamin D. Sample requirements for 24,25-(OH)₂-Vitamin D are 100uL of separated serum sent at room temperature. The ratio of 25-(OH)-Vitamin D to 24,25-(OH)₂-Vitamin D has a cut-off of >23 for being associated with altered Vitamin D status [8]</p> <p>Ultimately, the diagnosis is confirmed by identifying biallelic pathogenic variants. The Online Mendelian Inheritance in Man (OMIM) catalogue describes a range of mutations found in literature to cause IIH, including the Glu143del variant found in our patient [4 -> 5]. <i>CYP24A1</i> testing is part of the NHS England National Genomic Testing Directory within panel R256 for nephrolithiasis [9]</p> <p>Treatment of this condition is potentially simple to initiate but can be challenging to maintain. Primarily treatment should be aimed at reducing Vitamin D and calcium intake in addition to avoiding prolonged sun exposure. Short courses of steroids can be used, however in the long term this is not feasible and there are case reports of successful use of Fluconazole given this inhibits the 1-α-Hydroxylase enzyme [10].</p>
<p>Funding statement</p> <p>This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.</p>
<p>Declaration of interest</p> <p>NC, JT and RN have no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.</p>
<p>Patient consent</p> <p>RN discussed publication of this case directly with the patient via telephone appointment. Written signed consent was gained from the patient for publication of the submitted article and accompanying images.</p>
<p>Author contributions and acknowledgements</p> <p>NC contributed to arranging further vitamin D testing with referral laboratory and to the writing of the manuscript. JT contributed background data on Vitamin D metabolite analysis. RN contributed to direct care of the patient and writing of the manuscript.</p>
<p>References</p> <ol style="list-style-type: none"> 1. Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. <i>Endocr Rev.</i> 2016;37(5):521-547. doi:10.1210/er.2016-1070 2. Hypercalcaemia in infants and vitamin D. <i>BMJ</i> 1956 ;2:149-149. doi:10.1136/bmj.2.4985.149 3. Liu S, Quarles LD. How fibroblast growth factor 23 works. <i>J Am Soc Nephrol.</i> 2007 Jun;18(6):1637-47. doi: 10.1681/ASN.2007010068. 4. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, Ulrike J, Misselwitz J, Klaus G, Kuwertz-Broking

- E, Fehrenbach H et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. *New Eng J Med* 2001 365: 410-421. DOI: 10.1056/NEJMoa1103864
5. O'Neil MJF. Hypercalcaemia, Infantile Type 1 [Internet]. OMIM. 2011. [cited Sept 2020] Available from: <https://www.omim.org/entry/143880>
6. De Paolis E, Scaglione GL, De Bonis M, Minucci A, Capoluongo E. CYP24A1 and SLC34A1 genetic defects associated with idiopathic infantile hypercalcemia: from genotype to phenotype. *Clin Chem Lab Med*. 2019 Oct 25;57(11):1650-1667. doi: 10.1515/cclm-2018-1208
7. Supra-Regional Assay Service. Norfolk and Norwich University Hospital Bone Marker Service [Internet]. 2020 [cited Sept 2020]. Available from: <http://www.sas-centre.org/centres/bone-markers/norwich>
8. Tang JCY, Nicholls H, Piec I, Washbourne CJ, Dutton JJ, Jackson S, Greeves J, Fraser WD. Reference intervals for serum 24,25-dihydroxyvitamin D and the ratio with 25-hydroxyvitamin D established using a newly developed LC-MS/MS method. *Nutr Biochem*. 2017 Aug;46:21-29. DOI: 10.1016/j.jnutbio.2017.04.005
9. NHS England. "National Genomic Test Directory for rare and inherited disease [internet]. NHS England 2020. [cited Jun 2020]. Available from: <https://www.england.nhs.uk/wp-content/uploads/2018/08/Rare-and-Inherited-Disease-Eligibility-Criteria-November-2020-21.pdf>
10. Sayers J, Hynes AM, Srivastava S, Downen F, Quinton R, Darra HK, Sayer JA. Successful treatment of hypercalcaemia associated with a CYP24A1 mutation with fluconazole. *Clin Kidney J*. 2015;8(4):453-455. doi:10.1093/ckj/sfv028

Legends to tables/figures/videos

Table 1 - Summary of historical patient investigations - results described with accompanying reference ranges

Figure 1 – A summary of the Vitamin D metabolic pathway including enzymes and location of activity. The enzyme affected by IIH is highlighted by a red box. Red arrows indicate the expected changes in measureable vitamin D metabolites in IIH. Adapted from Figure 1A, Tebben et al [1].